NEW YORK, May 11, 2017 /PRNewswire/ --
Stock-Callers.com takes a closer look at the most recent performances of Radius
Waltham, Massachusetts headquartered Radius Health Inc.'s stock finished Wednesday's session 3.31% lower at $35.32 with a total trading volume of 723,129 shares. The stock is trading below their 50-day moving average by 8.08%. Shares of the Company, which develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the US, have a Relative Strength Index (RSI) of 39.73.
On May 01st, 2017, Radius Health reported its financial results for Q1 ended March 31st, 2017. Net loss for the quarter was $56.9 million; research and development expenses were $19.5 million; and general and administrative expenses were $38.1 million. As of March 31st, 2017, the Company had $282.1 million in cash, cash equivalents and marketable securities. Your complete research report on RDUS can be retrieved for free at:
Shares in Cambridge, Massachusetts headquartered bluebird bio Inc. rose 1.69%, ending yesterday's session at $90.45 with a total trading volume of 390,131 shares. The stock has gained 4.69% in the past month, 22.89% in the previous three months, and 46.60% on an YTD basis. The Company's shares are trading 2.72% above their 50-day moving average and 30.36% above their 200-day moving average. Moreover, shares of bluebird bio, which focuses on developing transformative gene therapies for severe genetic diseases and cancer, have an RSI of 54.19.
On May 02nd, 2017, bluebird bio announced that the Company has entered into a worldwide license agreement around its proprietary lentiviral vector platform with GlaxoSmithKline Intellectual Property Development Limited (GSK). Under terms of the agreement, GSK will non-exclusively license certain bluebird patent rights related to lentiviral vector technology to develop and commercialize gene therapies for Wiscott-Aldrich syndrome and metachromatic leukodystrophy-two, rare, genetic diseases. A free report on BLUE is just a click away at:
Universal Health Services
On Wednesday, King of Prussia, Pennsylvania headquartered Universal Health Services Inc.'s stock climbed 0.91%, to close the day at $123.61. A total volume of 428,149 shares was traded. The Company's shares have advanced 0.13% in the last one month, 8.73% in the previous three months, and 16.29% on an YTD basis. The stock is trading 1.09% and 3.00% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Universal Health Services, which through its subsidiaries, owns and operates acute care hospitals, behavioral health facilities, and ambulatory centers, have an RSI of 55.88.
On April 25th, 2017, Universal Health Services announced Q1 2017 financial results. Net income was $206.1 million, or $2.12 per diluted share, during Q1 2017, as compared to $190.8 million, or $1.93 per diluted share, during Q1 2016. Net revenues increased 6.7% to $2.61 billion during Q1 2017 compared to $2.45 billion during Q1 2016.
On April 27th, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with a decrease of the target price from $157 a share to $153 a share. Sign up for your complimentary research report on UHS at:
Shares in Brentwood, Tennessee-based LifePoint Health Inc. ended the day 2.67% higher at $63.55. A total volume of 363,294 shares was traded. The stock has gained 5.22% in the previous three months and 11.88% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 0.99% and 6.29%, respectively. Furthermore, shares of LifePoint Health, which through its subsidiaries, owns and operates community hospitals, regional health systems, physician practices, outpatient centers, and post-acute facilities in the US, have an RSI of 55.55.
On May 02nd, 2017, LifePoint Health announced that its management will participate in the Bank of America Merrill Lynch 2017 Health Care Conference, which will be held from May 16th, 2017 to May 18th, 2017 in Las Vegas, Nevada. The Company also announced that a live broadcast of the presentation will be available on Tuesday, May 16th, 2017, beginning at 3:40 p.m. PT on the Company's website. Register for free on Stock-Callers.com and download the latest research report on LPNT at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All